Ministère de la Santé, du Planning Familial et de la Protection Sociale, Antananarivo, Madagascar.
Am J Trop Med Hyg. 2012 Feb;86(2):203-10. doi: 10.4269/ajtmh.2012.11-0047.
Home management of malaria is recommended for prompt, effective antimalarial treatment in children less than five years of age. Compliance, safety, and effectiveness of the new fixed-dose artesunate-amodiaquine regimen used to treat suspected malaria were assessed in febrile children enrolled in a 24-month cohort study in two settings in Madagascar. Children with fever were asked to visit community health workers. Presumptive antimalarial treatment was given and further visits were scheduled for follow-up. The primary endpoint was the risk of clinical/parasitologic treatment failure. Secondary outcomes included fever/parasite clearance, change in hemoglobin levels, and frequency of adverse events. The global clinical cure rate was 98.4% by day 28 and 97.9% by day 42. Reported compliance was 83.4%. No severe adverse effects were observed. This study provides comprehensive data concerning the clinical cure rate obtained with artesunate-amodiaquine and evidence supporting the scaling up of home management of malaria.
家庭管理疟疾建议及时、有效抗疟治疗儿童年龄小于五岁。合规性、安全性和新的固定剂量青蒿琥酯-阿莫地喹方案用于治疗疑似疟疾的疗效评估在发热的儿童中参加了一项为期 24 个月的队列研究在马达加斯加的两个地区。有发热的儿童被要求访问社区卫生工作者。假定抗疟治疗，并进一步安排随访。主要终点是临床/寄生虫学治疗失败的风险。次要结局包括发热/寄生虫清除、血红蛋白水平的变化和不良事件的频率。全球临床治愈率为 98.4%，第 28 天和 97.9%，第 42 天。报告的合规性为 83.4%。未观察到严重不良影响。这项研究提供了有关青蒿琥酯-阿莫地喹获得的临床治愈率的综合数据，并为扩大疟疾家庭管理提供了证据支持。
